checkAd
    Startseite > Aktien > Coherus BioSciences > Nachrichten
    Coherus BioSciences
    Aktie
    ISIN: US19249H1032 WKN: A12ETZ SYM: 8C5 Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,7110
     
    EUR
    +6,54 %
    +0,1050 EUR
    Letzter Kurs 19:45:01 Tradegate
    Geldkurs
    19:48:20
    1,6895
     
    EUR
    5.400 STK
    Briefkurs
    19:48:20
    1,7105
     
    EUR
    2.900 STK

    Coherus BioSciences Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
    05.06.24 · globenewswire · Coherus BioSciences
    Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
    30.05.24 · globenewswire · Coherus BioSciences
    Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    23.05.24 · globenewswire · Coherus BioSciences
    Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
    23.05.24 · globenewswire · Coherus BioSciences
    Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    09.05.24 · globenewswire · Coherus BioSciences
    Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
    09.05.24 · globenewswire · Coherus BioSciences
    Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
    08.05.24 · globenewswire · Coherus BioSciences
    Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
    01.05.24 · globenewswire · Coherus BioSciences
    Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · Coherus BioSciences
    Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
    08.04.24 · globenewswire · Coherus BioSciences
    Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
    13.03.24 · globenewswire · Coherus BioSciences
    Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
    05.03.24 · globenewswire · Coherus BioSciences